PRKAA1 and invasive breast carcinoma: In order to assess the possible value of metformin as a sensitiser for radiotherapy of breast cancer and AMPK as a potential prognostic factor, the present study first sought to evaluate the expression of AMPK, the target of metformin, in radiotherapy treated early-stage invasive breast cancer patients.